Frontiers in Endocrinology · Oct 30, 2026
Association between the single-point insulin sensitivity estimator and hyperuricemia: evidence from four large cohorts
By Haomiao Yu, Jinfeng Cai, Xiaoqing Xi
Background The single-point insulin sensitivity estimator (SPISE) index has emerged as an innovative surrogate marker of insulin resistance. This study aimed to evaluate the association between SPISE and hyperuricemia (HUA), including incident HUA in a prospective cohort and prevalent HUA in cross-sectional cohorts. Methods Data were sourced from four cohorts: the China Health and Retirement Longitudinal Study (CHARLS, prospective cohort), the National Health and Nutrition Examination Survey (NHANES, cross-sectional), Renmin Hospital of Wuhan University (RHWU, cross-sectional), and Henan Provincial People’s Hospital (HPPH, cross-sectional). Multivariable logistic regression, restricted cubic spline (RCS) analysis, and receiver operating characteristic (ROC) curve analysis were employed to assess the association between SPISE and HUA. Results Data were drawn from two general-population cohorts (CHARLS, n = 6,230, prospective; NHANES, n = 29,588, cross-sectional) and two acute STEMI patient cohorts (RHWU, n = 1,245, cross-sectional; HPPH, n = 1,384, cross-sectional). Across all four cohorts, higher SPISE was significantly associated with lower odds of prevalent HUA in the cross-sectional cohorts and reduced risk of incident HUA in CHARLS after full adjustment: CHARLS (odds ratio [OR]= 0.79, 95% confidence interval [CI]= 0.75 - 0.83), NHANES (adjusted OR= 0.68, 95% CI= 0.66 - 0.70), RHWU (adjusted OR= 0.77, 95% CI= 0.71 - 0.85), and HPPH (adjusted OR= 0.82, 95% CI= 0.73 - 0.92). Compared with the lowest SPISE quartile (Q1), participants in the highest quartile (Q4) had significantly reduced risks of HUA, with adjusted ORs of 0.27 (0.20–0.36) in CHARLS, 0.16 (0.14–0.19) in NHANES, 0.34 (0.23–0.51) in RHWU, and 0.44 (0.28–0.67) in HPPH. RCS analysis confirmed a significant inverse dose–response relationship between SPISE and HUA risk. The discriminatory performance of SPISE for HUA was superior to that of other lipid-related biomarkers. Subgroup analyses further supported the robustness of these findings. Conclusion Higher SPISE levels were associated with lower odds of prevalent HUA in the cross-sectional cohorts and a reduced risk of incident HUA in CHARLS. These findings suggest that SPISE may be a promising candidate marker for HUA risk stratification; however, external prospective validation is required before routine clinical use for hyperuricemia risk screening.